Related Experiment Video
Updated: Jul 4, 2025
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Xylazine Use Among People Who Inject Drugs, Philadelphia 2022
Marissa Tan1, Tanner Nassau, Danica Kuncio
1From the Division of Workforce Development, Epidemiology Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA (MT); Division of HIV Health, Philadelphia Department of Public Health, Philadelphia, PA (MT, TN, DT, KAB); Division of Disease Control Hepatitis, Philadelphia Department of Public Health, Philadelphia, PA (MT, DK); and Division of Substance Use Prevention and Harm Reduction, Philadelphia Department of Public Health, Philadelphia, PA (MT, DH, DTS).
Objectives:
Xylazine is commonly mixed with illicit opioids in Philadelphia, and potential associations with wound issues, infectious diseases, and overdoses are of public health concern. We used data from the National HIV Behavioral Surveillance Survey among persons who inject drugs (PWIDs) in Philadelphia to better identify individuals at risk and inform patients and clinicians about xylazine risk factors.
Methods:
We compared characteristics of participants who reported using xylazine to those who reported not using xylazine in the past 12 months. Among those who reported xylazine use, we compared characteristics between people who prefer and did not prefer to use xylazine.
Results:
In this sample of PWIDs, most prefer not to use xylazine, yet use is common. Compared with PWIDs not using xylazine, PWIDs who use xylazine were more likely to have recent homelessness, polysubstance use, overdose history, and hepatitis C virus infection ( P < 0.05 for all comparisons). Compared with concordant xylazine use, discordant xylazine use was associated with lower preference for fentanyl, heroin as the primary injection drug, and lower use of syringe service programs ( P < 0.05 for all comparisons).
Conclusions:
Public health entities should prioritize studying the use and health effects of xylazine in their jurisdictions and consider supporting point-of-care and drug-checking surveillance in addition to raising awareness of xylazine in the drug supply.
